Abstract: Objective 　To evaluate if using a panel of markers such as CD10, CD30, CD138, Bcl26 and Mum1/ IRF4 by immunohistochemist ry defines prognosis in patient s with diffuse large B2cell lymphoma (DLBCL) . Methods 　Immunohistochemical stains for the above markers were performed on paraffin2em2 bedded tissues of 73 patient s consecutively diagnosed with DLBCL. Results 　The univariate analysis dem2 onst rated that the expression of Bcl26 and Mum21 were significant prognosis factors, with P values of 0. 028 and 0. 001. CD138 ( P = 0. 210) may play an important role as a poor prognostic marker. Moreover, when the patient s were subdivided according to Hans, there is no difference between GCB (19 patient s, 26 %) and non2GCB(54 patient s, 74 %) in survival rate ( P = 0. 959) . Using the four group s classification of Chang, 5 patient s (6. 9 %) were subclassified as pattern A, 29 (39. 7 %) as B and C separately, and 10 (13. 7 %) as D. Among the four patterns, pattern B showed a better survival rate, pattern D had a signifi2 cantly lower survival rate, and pattern C is between the two groups. Conclusion 　In the present study, the expression of Bcl26 and Mum21 were associated with particular clinicopathologic features and outcome, which were favourable prognostic factors. CD138 may play an important role as a poor prognostic marker.